These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37624820)

  • 21. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension.
    Coca A; Kreutz R; Manolis AJ; Mancia G
    J Hypertens; 2020 Oct; 38(10):1890-1898. PubMed ID: 32890261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
    J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
    Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J
    Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial.
    Lafeber M; Grobbee DE; Schrover IM; Thom S; Webster R; Rodgers A; Visseren FL; Bots ML; Spiering W
    Int J Cardiol; 2015 Feb; 181():193-9. PubMed ID: 25528311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
    Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ
    Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between birth characteristics and coronary disease risk factors among fifth graders.
    Mullett MD; Cottrell L; Lilly C; Gadikota K; Dong L; Hobbs G; Neal WA
    J Pediatr; 2014 Jan; 164(1):78-82. PubMed ID: 24120018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laparoscopic Roux-En-Y Gastric Bypass Improves Lipid Profile and Decreases Cardiovascular Risk: a 5-Year Longitudinal Cohort Study of 1048 Patients.
    Gero D; Favre L; Allemann P; Fournier P; Demartines N; Suter M
    Obes Surg; 2018 Mar; 28(3):805-811. PubMed ID: 28971303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
    Bangalore S; Fayyad R; Messerli FH; Laskey R; DeMicco DA; Kastelein JJ; Waters DD
    Am J Cardiol; 2017 Feb; 119(3):379-387. PubMed ID: 27939230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Dader Method for pharmaceutical care on control of blood pressure and total cholesterol in outpatients with cardiovascular disease or cardiovascular risk: EMDADER-CV randomized controlled trial.
    Amariles P; Sabater-Hernández D; García-Jiménez E; Rodríguez-Chamorro MÁ; Prats-Más R; Marín-Magán F; Galán-Ceballos JA; Jiménez-Martín J; Faus MJ
    J Manag Care Pharm; 2012 May; 18(4):311-23. PubMed ID: 22548691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hypertension, dyslipoproteinemia and BMI-category characterise the cardiovascular risk in overweight or obese children and adolescents: data of the BZgA-observational study (EvAKu-J-project) and the KiGGS-study].
    Flechtner-Mors M; Thamm M; Rosario AS; Goldapp C; Hoffmeister U; Mann R; Bullinger M; van Egmond-Fröhlich A; Ravens-Sieberer U; Reinehr T; Westenhöfer J; Holl RW
    Klin Padiatr; 2011 Dec; 223(7):445-9. PubMed ID: 22012610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
    Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
    Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of body mass index and waist circumference on the cardiovascular risk and all-cause death in a general population: data from the PAMELA study.
    Bombelli M; Facchetti R; Fodri D; Brambilla G; Sega R; Grassi G; Mancia G
    Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):650-6. PubMed ID: 22633796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
    Yusuf S; Pais P; Sigamani A; Xavier D; Afzal R; Gao P; Teo KK
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):463-71. PubMed ID: 22787067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events.
    Boersma C; Postma MJ; Visser ST; Atthobari J; de Jong PE; de Jong-van den Berg LT; Gansevoort RT;
    Br J Clin Pharmacol; 2008 May; 65(5):723-32. PubMed ID: 18241288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The obesity paradox, weight loss, and coronary disease.
    Lavie CJ; Milani RV; Artham SM; Patel DA; Ventura HO
    Am J Med; 2009 Dec; 122(12):1106-14. PubMed ID: 19682667
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.